Literature DB >> 22447043

The J-curve revisited: a therapeutic dilemma.

Edward J Filippone1, Andrew Foy.   

Abstract

The J-curve in hypertension treatment refers to the relationship between achieved diastolic blood pressure (BP) and cardiovascular morbidity and mortality, specifically related to coronary heart disease (CHD). As diastolic BP decreases below a certain threshold or nadir, the risk of cardiovascular events increases. This phenomenon was first described over 30 years ago and its significance has been debated ever since. We review in detail the literature for and against the existence of this J-curve and discuss its purported pathophysiology. Most notably, recent post hoc analyses of large contemporary randomized trials in patients with documented CHD strongly support its existence. Given the current emphasis on strict BP control, especially in high-risk patients like those with CHD, diabetes, and chronic kidney disease, we discuss the implications this J-curve may have for treating hypertension in the individual patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447043     DOI: 10.1097/CRD.0b013e3182564a34

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  3 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 2.  New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease.

Authors:  Achim Leo Burger; Edita Pogran; Marie Muthspiel; Christoph Clemens Kaufmann; Bernhard Jäger; Kurt Huber
Journal:  Biomedicines       Date:  2022-04-22

3.  Prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: a multivariate analysis.

Authors:  Helge Bruns; Vladimir J Lozanovski; Daniel Schultze; Norbert Hillebrand; Ulf Hinz; Markus W Büchler; Peter Schemmer
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.